Leerink Swann Reiterates a Hold Rating on Henry ScheinBy Jason Carr
“We view growth in the Technology Division as healthy, and a significant long-term positive. Model Under Review. We are currently revisiting our estimates in light of the new FY:17 guidance. Our model is under review.”
According to TipRanks.com, Larsen is a 2-star analyst with an average return of 0.1% and a 35.9% success rate. Larsen covers the Technology sector, focusing on stocks such as Quality Systems, Everyday Health, and Evolent Health.
Henry Schein has an analyst consensus of Moderate Buy, with a price target consensus of $181.75.
The company has a one year high of $183 and a one year low of $142.64. Currently, Henry Schein has an average volume of 679.7K.
Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2016, Paul Brons, a Director at HSIC sold 3,381 shares for a total of $554,585.
Henry Schein, Inc. engages in the provision of providing health care products and services to medical, dental, and veterinary office-based practitioners. It operates through Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology and Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.